Introduction
============

Chronic obstructive pulmonary disease (COPD) is a chronic pulmonary inflammatory disorder, and pathological changes are observed in the proximal airways, peripheral airways, lung parenchyma, and pulmonary vasculature. These inflammatory and structural changes lead to various physiological changes in lung function, including airflow limitation, air trapping, ventilation heterogeneity, and gas exchange abnormalities (Rabe et al., [@B28]).

In the long-term management of stable COPD, long-acting bronchodilators are central to the pharmacologic treatment (Celli and MacNee, [@B10]; Rabe et al., [@B28]). The use of inhaled corticosteroids (ICS) is recommended to reduce the frequency of exacerbations in symptomatic patients with a forced expiratory volume in 1 s (FEV~1~) of less than 50% of predicted and repeated exacerbations (Mahler et al., [@B20]; Calverley et al., [@B7]; Jones et al., [@B15]; Szafranski et al., [@B33]; Spencer et al., [@B32]). To date, the effectiveness of ICS for patients with COPD remains controversial (Pauwels et al., [@B26]; Vestbo et al., [@B34]; Burge et al., [@B6]; Lung Health Study Research Group, [@B19]). Recently, ICS/inhaled long-acting beta~2~-agonists (LABA) combination therapy has become widely used in clinical practice, achieving profound improvements of pulmonary function, symptoms and health-related quality of life, and preventing exacerbations compared with placebo or either monotherapy alone (Mahler et al., [@B20]; Calverley et al., [@B7], [@B8]; Hanania et al., [@B14]; Szafranski et al., [@B33]; Wedzicha et al., [@B35]). However, a meta-analysis has clarified that the efficacy of ICS/LABA combination therapy compared with LABA monotherapy on pulmonary function shows statistical heterogeneity (Rodrigo et al., [@B29]). In addition, ICS therapy may lead to increased risk of pneumonia in the patients with COPD (Drummond et al., [@B12]; Wedzicha et al., [@B35]; Rodrigo et al., [@B29]; Singh et al., [@B31]). These findings strongly suggest that it is important to clarify a clinical marker that has high specificity for identifying COPD patients for whom ICS/LABA combination would be beneficial. Importantly, the effects of ICS in COPD are much less dramatic than in asthma and the long-term safety of ICS in patients with COPD is not well established.

The aim of this study was to assess a specific marker for predicting the efficacy of ICS/LABA combination therapy for pulmonary function. We investigated the relationship between the baseline levels of FE~NO~, serum markers, and changes in pulmonary function by additive treatment of fluticasone propionate (FP)/salmeterol (SAL) combination to tiotropium.

Materials and Methods
=====================

Study subjects
--------------

Fourteen stable COPD patients receiving long-acting muscarinic receptor antagonist (tiotropium 18 μg/day) were consecutively enrolled from the outpatient clinic of Wakayama Medical University Hospital. COPD was diagnosed according to the guidelines of the Global Initiative for Chronic Obstructive Lung Disease (Rabe et al., [@B28]). All subjects had airflow limitation with FEV~1~ \< 80% of predicted and FEV~1~/forced vital capacity (FVC) ratio \<70%. They had a smoking history of more than 10 pack-years and had emphysema on high-resolution computed tomography (HRCT) of the lungs. Current smokers were excluded because of the influence of smoking on the exhaled nitric oxide (FE~NO~) levels (McSharry et al., [@B24]). Subjects who had histories and symptoms of atopic rhinitis, chronic rhinosinusitis, atopic dermatitis, food allergy, asthma, or other lung diseases were carefully excluded from the study. Those who had an exacerbation of COPD in the 4-weeks preceding the study were not included. Rescue use of salbutamol (200 μg as needed) for symptom relief was allowed. The study subjects who had been using LABA, ICS, ICS/LABA combination, oral beta~2~-agonists, regular use of inhaled short-acting beta~2~-agonists, regular use of inhaled, short-acting muscarinic receptor antagonists, and slow release theophylline were not allowed such use for at least 4 weeks before and during the study. The protocol was approved by the local ethics committee and performed after written informed consent was obtained from each subject.

Study design
------------

Pulmonary function test, FE~NO~ measurement, blood sampling, and HRCT of lungs were performed on the first visit. After assessment of the baseline values, FP/SAL (250/50 μg) was added twice daily for 12 weeks, and then pulmonary function test and FE~NO~ measurement were repeated. These variables were measured 2--4 h prior to the dosing of tiotropium and FP/SAL (Figure [1](#F1){ref-type="fig"}).

![**Study design**.](fphar-02-00036-g001){#F1}

Pulmonary function testing
--------------------------

Forced vital capacity, FEV~1~, forced expiratory flow (FEF), slope of the single breath nitrogen washing curve (ΔN~2~), total lung capacity (TLC), residual volume (RV), and diffusion lung carbon monoxide (DLCO) were evaluated using a dry rolling seal spirometer (CHESTAC-8800; Chest, Inc., Tokyo, Japan).

Exhaled NO measurement
----------------------

FE~NO~ was measured in accordance with the current guidelines (ATS/ERS, [@B2]) using a chemoluminescence analyzer (modified NA-623N^®^; Chest, Inc., Tokyo, Japan). Exhalations were repeated to obtain two acceptable values that agreed within 10% deviation, and the average of these two values was registered. All subjects were fasted for 1 h before the measurements.

Blood sampling
--------------

C-reactive protein (CRP), complete blood cell count, differential count of leukocytes, total serum immunoglobulin E (IgE) levels, and specific IgE for common allergens including *Dermatophagoides pteronyssinus* (DP), *Dermatophagoides farina* (DF), house dust 1 (HD1), house dust 2 (HD2), were examined. Positive specific IgE to at least one allergen was assumed to confirm a diagnosis of atopy.

Statistical analysis
--------------------

Statistical analysis of changes in pulmonary function and FE~NO~ were assessed using Wilcoxon signed-ranks test. Spearman's rank correlations were calculated to determine the relative changes between physiologic parameters and continuous data (eosinophil cell counts, total serum IgE, and FE~NO~ values). Comparison between atopic and non-atopic subjects was made by Mann--Whitney *U*-tests. The results are presented as mean ± SE. A value of *p* \< 0.05 was considered to be significant.

Results
=======

The baseline characteristics are listed in Table [1](#T1){ref-type="table"}. All subjects were ex-smokers, and males were over-represented. The majority (65%) of the study subjects was stage 2, four were stage 3 and one was stage 4. The mean FE~NO~ level was 36.4 ppb, and four subjects were defined as having atopy. The mean FE~NO~ levels were similar between the subjects with or without atopy (atopy+, 43.6 ppb; atopy−, 33.5 ppb; *p* = 0.63). Table [2](#T2){ref-type="table"} shows the lung function and FE~NO~ values before and 12-weeks after treatment with FP/SAL combination therapy. The treatment with FP/SAL significantly improved FVC, FEV~1~, %FEV~1~, %FEF~75%FVC~, and ΔN~2~ (all *p* \< 0.05). The median change of FEV~1~ was 0.13 L ranging from −0.11 to 0.40 L. The mean FE~NO~ level was also significantly reduced by the treatment with FP/SAL (*p* \< 0.05).

###### 

**Baseline characteristics of the study subjects**.

  Number (female/male)                              14 (2/12)
  ------------------------------------------------- --------------
  Age (years)                                       70.0 ± 5.2
  Body mass index (kg/m^2^)                         22.7 ± 1.9
  Pack years (years)                                52.7 ± 8.5
  GOLD classification (stage2/stage3/stage4; *n*)   9/4/1
  FE~NO~ (ppb)                                      36.4 ± 4.7
  White blood cells (/μL)                           5158 ± 274
  Blood Eosinophils (/μL)                           158 ± 38
  C-reactive protein (mg/Dl)                        0.13 ± 0.05
  Immunoglobulin E RIST (IU/mL)                     170.6 ± 47.5
  Immunoglobulin E RAST for DP/DF/HD (*n*)          4/3/4

*GOLD, Global Initiative for Chronic Obstructive Lung Disease; FE~NO~, fraction of exhaled nitric oxide; DP, *Dermatophagoides pteronyssinus*; DF, *Dermatophagoides farina*; HD, house dust. All values are mean ± SE*.

###### 

**Lung function and exhaled nitric oxide before and after treatment with inhaled fluticasone/salmeterol combination**.

                       Before         After          Difference (range)     *p*-value
  -------------------- -------------- -------------- ---------------------- -----------
  FVC (L)              2.99 ± 0.17    3.12 ± 0.19    0.15 (−0.15 to 0.64)   \<0.05
  %FVC (%)             93.0 ± 4.2     96.1 ± 4.9     3.1 (−5.2 to 15.9)     0.16
  FEV~1~ (L)           1.50 ± 0.11    1.63 ± 0.10    0.13 (−0.11 to 0.40)   \<0.05
  FEV~1~/FVC (%)       51.4 ± 3.8     54.3 ± 3.9     2.9 (−3.1 to 16.6)     0.16
  %FEV~1~ (%)          57.6 ± 4.4     62.0 ± 3.6     4.4 (−8.7 to 15.9)     \<0.05
  %FEF~50%FVC~ (%)     21.5 ± 3.5     24.0 ± 3.9     2.6 (−9.0 to 12.1)     0.11
  %FEF~75%FVC~ (%)     20.7 ± 2.7     24.1 ± 3.5     3.5 (−12.7 to 14.1)    \<0.05
  %TLC (%)             100.1 ± 0.3    105.8 ± 0.3    5.7 (−6.6 to 32.9)     0.11
  %RV (%)              120.1 ± 14.7   112.8 ± 15.2   −7.3 (−78.1 to 64.3)   0.55
  ΔN~2~ (%)            3.07 ± 0.36    2.44 ± 0.24    −0.6 (−2.6 to 0.8)     \<0.05
  %DL~CO~/*V*~A~ (%)   64.9 ± 7.8     67.4 ± 7.7     2.6 (−10.7 to 17.6)    0.35
  FE~NO~ (ppb)         36.4 ± 4.7     23.9 ± 3.6     −12.5 (−52.2 to 4.4)   \<0.05

*FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 s; FEF, forced expiratory flow; TLC, total lung capacity; RV, residual volume; ΔN~2~, slope of the single breath nitrogen washing curve; DL~CO~, diffusion lung carbon monoxide; *V*~A~, alveolar volume; FE~NO~, fraction of exhaled nitric oxide. All values are mean ± SE*.

The baseline FE~NO~ level was not associated with the changes in FEV~1~ (*r* = −0.16, *p* = 0.60), but significantly correlated with the changes in ΔN~2~ (*r* = −0.69, *p* \< 0.01; Figure [2](#F2){ref-type="fig"}). The relationship between the baseline FE~NO~ levels and the changes in other pulmonary physiological parameters were not significant. Among the serum markers, the subjects with positive specific IgE showed significantly higher improvement in FEV~1~ (*p* \< 0.05), but not in ΔN~2~ (Figure [3](#F3){ref-type="fig"}). Other serum markers including blood eosinophils, CRP, and total IgE levels were not correlated with the changes in any physiological parameters.

![**Correlation between baseline levels of FE~NO~ and FP/SAL-mediated changes in FEV~1~**(A)** and slope of the single breath nitrogen washing curve \[ΔN~2~**(B)**\]**. The lines correspond to the fitted regression of the equation. Baseline ΔN~2~ values/ΔN~2~ values after FP/SAL combination treatment was defined as ΔN~2~ ratio.](fphar-02-00036-g002){#F2}

![**Scatter plots of FP/SAL-mediated changes in FEV~1~**(A)** and slope of the single breath nitrogen washing curve \[ΔN~2~**(B)**\] values in the subjects with positive or negative specific IgE results**.](fphar-02-00036-g003){#F3}

From the previous results, the baseline FE~NO~ levels and positive specific IgE were significantly associated with airway obstructive changes assessed by FEV~1~ and ΔN~2~. Therefore, FE~NO~ and atopy were selected and their sensitivity and specificity for predicting a significant improvement in FEV~1~ (greater than 200 mL) were analyzed. The rationale for selecting 35 ppb as a cutoff point for FE~NO~ was based on previously reported upper reference ranges in FE~NO~ in the Japanese adult population (Matsunaga et al., [@B23]). In our study, as shown in Table [3](#T3){ref-type="table"}, 5 of 14 COPD subjects (36%) showed a significant improvement in FEV~1~ by additive FP/SAL therapy. A baseline FE~NO~ level \>35 ppb yielded 80.0% sensitivity and 66.7% specificity for identifying the subjects with significant improvement in FEV~1~, with a positive predictive value (PPV) of 57.1% and negative predictive value (NPV) of 85.7%. A positive result of specific IgE (atopy+) yielded 60.0% sensitivity and 88.9% specificity of an improvement in FEV~1~, with PPV of 75.0% and NPV of 80.0%. When combined with FE~NO~ \> 35 ppb and atopy+, it showed 40% of sensitivity and 100.0% specificity, with a PPV of 100.0% and NPV of 75.0% for FEV~1~ improvement. Alternatively, COPD subjects with FE~NO~ ≤ 35 ppb and atopy− did not show significant improvement in FEV~1~ by additive treatment of FP/SAL combination to tiotropium (Figure [4](#F4){ref-type="fig"}).

###### 

**Sensitivity, specificity, positive predictive values (PPVs), and negative predictive values (NPVs) at FE~NO~ \> 35 ppb, atopy+, and combined with FE~NO~ \> 35 ppb and atopy+ for predicting FEV~1~ improvement greater than 200 mL**.

  Marker                        Sensitivity (%)   Secificity (%)   PPV (%)   NPV (%)
  ----------------------------- ----------------- ---------------- --------- ---------
  FE~NO~ \> 35 ppb              80.0              66.7             57.1      85.7
  Atopy+                        60.0              88.9             75.0      80.0
  FE~NO~ \> 35 ppb and atopy+   40.0              100.0            100.0     75.0

![**Distribution of the subjects whose FEV~1~ was increased greater than 12% by FP/SAL combination treatment stratified by baseline FE~NO~ level and specific IgE results**.](fphar-02-00036-g004){#F4}

Discussion
==========

This is the first study to identify that combining FE~NO~ and specific IgE appears to be a useful marker for predicting the response to ICS/LABA of airflow limitation in COPD. We demonstrated that FVC, FEV~1~, and ΔN~2~ values, as well as the FE~NO~ levels, were significantly improved by additional treatment with FP/SAL. The increased FE~NO~ levels at baseline and atopy+ were significantly associated with airway obstructive changes assessed by FEV~1~ and ΔN~2~. Furthermore, COPD subjects with FE~NO~ ≤ 35 ppb and atopy− did not show significant improvement in FEV~1~.

Use of ICS is recommended to reduce the frequency of exacerbations in symptomatic patients with a FEV~1~ of less than 50% predicted and repeated exacerbations (Mahler et al., [@B20]; Calverley et al., [@B7]; Jones et al., [@B15]; Szafranski et al., [@B33]; Spencer et al., [@B32]; Rabe et al., [@B28]). ICS/LABA combination therapy has obtained widespread acceptance in clinical practice. In the largest systematic review designed to assess the safety and efficacy of the regular use of ICS/LABA compared with the use of LABA alone in stable with moderate-to-very severe COPD, treatment with ICS/LABA significantly increased the risk of not only pneumonia, but also otopharyngeal candidiasis and viral respiratory infections (Rodrigo et al., [@B29]). Furthermore, a meta-analysis has clarified that the efficacy of ICS/LABA combination therapy compared with LABA monotherapy on pulmonary function showed statistical heterogeneity (Rodrigo et al., [@B29]). Therefore, the identification of a specific marker for predicting the efficacy of ICS/LABA would be useful in the treatment of COPD.

We showed that the FE~NO~ levels were significantly improved by the additional treatment with ICS/LABA. This finding is consistent with those of previous studies on steroid therapy in patients with COPD (Zietkowski et al., [@B37]; Kunisaki et al., [@B16]; Lehtimaki et al., [@B17]). Among patients with COPD, it has been proposed that steroid responsiveness is related to eosinophilic airway inflammation (Chanez et al., [@B11]). Several studies showed that the level of sputum eosinophils can predict the response to a short course of oral prednisolone or ICS in COPD (Pizzichini et al., [@B27]; Brightling et al., [@B4], [@B3]; Leigh et al., [@B18]). Recently, one study showed that FE~NO~ can predict the response to oral prednisolone (Dummer et al., [@B13]) and three studies showed that FE~NO~ can predict the response to ICS in COPD (Zietkowski et al., [@B37]; Kunisaki et al., [@B16]; Lehtimaki et al., [@B17]). These results suggest that there is a subgroup with eosinophilic inflammation among COPD patients, and that the detection of eosinophilic inflammation could be useful for predicting the efficacy of steroid therapy.

In the present study, when FE~NO~ was \>35 ppb, the sensitivity was 0.80 and the specificity was 0.67 for the subjects whose FEV~1~ was increased greater than 12% by FP/SAL combination treatment, although the baseline FE~NO~ was not correlated with the changes in FEV~1~ after combined ICS/LABA. A relationship between the baseline FE~NO~ levels and steroid-mediated changes in the pulmonary physiological parameters has been reported in several previous studies (Zietkowski et al., [@B37]; Kunisaki et al., [@B16]; Dummer et al., [@B13]; Lehtimaki et al., [@B17]). The baseline FE~NO~ was a predictor of the increase in FEV~1~ by steroid therapy (Dummer et al., [@B13]), and high levels of bronchial NO flux were found to be related to symptom relief and improvement of the airway obstruction during treatment with inhaled fluticasone (Lehtimaki et al., [@B17]). The reason that the baseline FE~NO~ was not correlated with the changes in FEV~1~ in our study may be due not only to the effect of ICS but also that of LABA. The results of these studies and ours suggested that the measurement of FE~NO~ may enable the selection of individual COPD patients who could benefit from steroid therapy.

Interestingly, the present study showed a significant correlation between positive specific IgE and the degree of improvement in FEV~1~. Atopy was found to be associated with increased FE~NO~ irrespective of asthma (Malinovschi et al., [@B21]) and is known to favor eosinophilic inflammation (Schleich et al., [@B30]). This is the first report showing that specific IgE is a useful marker to predict the efficacy of ICS/LABA combination in COPD patients. In contrast, the peripheral blood eosinophils and the total serum IgE were insensitive markers for predicting the efficacy, which is compatible with previous data (Brightling et al., [@B3]).

When FE~NO~ \> 35 ppb and/or atopy+ were combined, the sensitivity was 1.0 and the specificity was 0.56 for the subjects whose FEV~1~ was increased greater than 12% by FP/SAL combination treatment. This sensitivity was higher than the 0.6 when FE~NO~ \> 35 ppb. Combining the measurement of FE~NO~ and specific IgE may become a predictor of COPD patients who could benefit from ICS/LABA combination. More importantly, the specificity of a low (normal) FE~NO~ (≤35 ppb) and atopy− was 100%, indicating that a combining the measurement of FE~NO~ and specific IgE would help the clinicians to avoid prescribing ICS/LABA treatment for non-responsive patients.

Inhaled corticosteroids/LABA combination therapy improved FEV~1~ by 130 mL from the baseline value, which is smaller than the results from previous studies (Mahler et al., [@B20]; Hanania et al., [@B14]; O'Donnell et al., [@B25]). This difference is probably due to the fact that the patients in our study already received treatment with muscarinic receptor antagonist. In fact, the degree of improvement in FEV~1~ in this study was similar to that reported previously when combined ICS/LABA was added for patients with COPD who had already been treated with tiotropium (Aaron et al., [@B1]; Cazzola et al., [@B9]; Welte et al., [@B36]). Furthermore, ICS/LABA combination therapy improved the slope of the single breath nitrogen washing curve which reflects ventilation heterogeneity (Buist and Ross, [@B5]), but did not decrease TLC and RV in the current study. O'Donnell et al. ([@B25]) have shown that ICS/LABA combination therapy improved lung hyperinflation, but our data did not show reduced FRC and RV levels. We used the helium gas dilution method to assess the lung volume, whereas they measured the lung volume by body plethysmography. The discrepancy in the results is possibly due to this difference in the measurement of the lung volume.

There are several limitations in the current study. First, the value of FE~NO~ was relatively higher than that of previously reported data in patients with COPD (Dummer et al., [@B13]; Lehtimaki et al., [@B17]). Lehtimaki et al. ([@B17]) described that, when assessing the role of FE~NO~ in COPD, it is important to exclude asthma since concomitant asthma with more eosinophilic and steroid-sensitive inflammation might bias the results. In the present study, although we carefully excluded patients with asthma, as none of the subjects had a previous diagnosis or clinical history of asthma, atopic rhinitis, atopic dermatitis, or food allergy, we might not have been able to completely exclude COPD patients with an asthmatic component. Marsh et al. ([@B22]) reported that asthma was a predominant COPD phenotype, being present in 55% of their subjects with COPD. Second, since this study consisted of very few subjects, further confirmation of the present results is needed in a large-scale randomized control trial. Finally, in the present study, we analyzed the efficacy of ICS/LABA only on pulmonary functions. Predictive factors for the effects on quality of life and inhibition of exacerbation, which are also important points of COPD pharmacotherapy, should be studied in the future.

In summary, we have shown that the increased FE~NO~ levels and atopy appear to be useful predictors of ICS/LABA-mediated pulmonary function improvements in COPD.
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